Review



dna pk  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Tocris dna pk
    Dna Pk, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 204 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dna pk/product/Tocris
    Average 95 stars, based on 204 article reviews
    dna pk - by Bioz Stars, 2026-03
    95/100 stars

    Images



    Similar Products

    95
    Tocris dna pk
    Dna Pk, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dna pk/product/Tocris
    Average 95 stars, based on 1 article reviews
    dna pk - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    93
    MedChemExpress dna pk inhibitor nu 7441 dc3100
    Dna Pk Inhibitor Nu 7441 Dc3100, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dna pk inhibitor nu 7441 dc3100/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    dna pk inhibitor nu 7441 dc3100 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    94
    Tocris nu 7441
    Nu 7441, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nu 7441/product/Tocris
    Average 94 stars, based on 1 article reviews
    nu 7441 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Tocris nu7441
    (A) Immunoblot of U2OS cells that are wild type (WT) or knocked out for the indicated genes. See for the IR sensitivity analysis of each of these cells. (B) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO received 5 Gy of IR before being post-incubated 5 or 60 min and processed for Ku foci imaging. Representative pictures are shown on the left. Ku foci intensity was measured and normalized to the average Ku foci intensity measured after 5 Gy of IR in WT U2OS to compute the fold change in Ku foci intensity in each condition, depicted on the graph on the right. (C) WT or PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 60 min before being processed for Ku foci imaging. Cells were pre-treated with nedisertib (PKi) for 1 h before treatment where indicated. Fold change in Ku foci intensity in each condition is displayed. (D) PKcs-KO or LIG4-KO U2OS cells received 5 Gy of IR and were post-incubated for the indicated time with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the changes in Ku foci intensity with NEDi versus without NEDi (DMSO) are shown in the graph on the right. The graph depicting the fold change in Ku foci intensity in each condition corresponds to . (E) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 5 or 60 min with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the change in Ku foci intensity with NEDi versus without NEDi (DMSO) is plotted in the graph on the right. The graph in depicts the fold change in Ku foci intensity in each condition. (F) WT, PKcs-KO, or LIG4-KO U2OS cells incubated with 3 μM <t>NU7441</t> (PKi) were treated with 3 nM Cali for 1 h with or without NEDi before being collected and processed to separate the chromatin fraction from the soluble fraction, which were both analyzed by immunoblotting. SAF-A and nucleolin were used as loading controls for the chromatin and the soluble fraction, respectively. (G) Control (immunoglobulin G [IgG]) or anti-Ku immunoprecipitation was performed from the soluble fractions of PKcs-KO U2OS to monitor Ku ubiquitination in response to Cali with or without NEDi. For all panels, error bars represent SD from the means of n ≥ 3 independent experiments. p values are as follow: ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Scale bars, 5 μm.
    Nu7441, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nu7441/product/Tocris
    Average 94 stars, based on 1 article reviews
    nu7441 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Tocris dna pkcs kinase inhibitor nu 7441
    (A) Immunoblot of U2OS cells that are wild type (WT) or knocked out for the indicated genes. See for the IR sensitivity analysis of each of these cells. (B) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO received 5 Gy of IR before being post-incubated 5 or 60 min and processed for Ku foci imaging. Representative pictures are shown on the left. Ku foci intensity was measured and normalized to the average Ku foci intensity measured after 5 Gy of IR in WT U2OS to compute the fold change in Ku foci intensity in each condition, depicted on the graph on the right. (C) WT or PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 60 min before being processed for Ku foci imaging. Cells were pre-treated with nedisertib (PKi) for 1 h before treatment where indicated. Fold change in Ku foci intensity in each condition is displayed. (D) PKcs-KO or LIG4-KO U2OS cells received 5 Gy of IR and were post-incubated for the indicated time with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the changes in Ku foci intensity with NEDi versus without NEDi (DMSO) are shown in the graph on the right. The graph depicting the fold change in Ku foci intensity in each condition corresponds to . (E) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 5 or 60 min with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the change in Ku foci intensity with NEDi versus without NEDi (DMSO) is plotted in the graph on the right. The graph in depicts the fold change in Ku foci intensity in each condition. (F) WT, PKcs-KO, or LIG4-KO U2OS cells incubated with 3 μM <t>NU7441</t> (PKi) were treated with 3 nM Cali for 1 h with or without NEDi before being collected and processed to separate the chromatin fraction from the soluble fraction, which were both analyzed by immunoblotting. SAF-A and nucleolin were used as loading controls for the chromatin and the soluble fraction, respectively. (G) Control (immunoglobulin G [IgG]) or anti-Ku immunoprecipitation was performed from the soluble fractions of PKcs-KO U2OS to monitor Ku ubiquitination in response to Cali with or without NEDi. For all panels, error bars represent SD from the means of n ≥ 3 independent experiments. p values are as follow: ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Scale bars, 5 μm.
    Dna Pkcs Kinase Inhibitor Nu 7441, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dna pkcs kinase inhibitor nu 7441/product/Tocris
    Average 94 stars, based on 1 article reviews
    dna pkcs kinase inhibitor nu 7441 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    95
    Tocris dna pk inhibitor nu7441
    (A) Immunoblot of U2OS cells that are wild type (WT) or knocked out for the indicated genes. See for the IR sensitivity analysis of each of these cells. (B) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO received 5 Gy of IR before being post-incubated 5 or 60 min and processed for Ku foci imaging. Representative pictures are shown on the left. Ku foci intensity was measured and normalized to the average Ku foci intensity measured after 5 Gy of IR in WT U2OS to compute the fold change in Ku foci intensity in each condition, depicted on the graph on the right. (C) WT or PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 60 min before being processed for Ku foci imaging. Cells were pre-treated with nedisertib (PKi) for 1 h before treatment where indicated. Fold change in Ku foci intensity in each condition is displayed. (D) PKcs-KO or LIG4-KO U2OS cells received 5 Gy of IR and were post-incubated for the indicated time with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the changes in Ku foci intensity with NEDi versus without NEDi (DMSO) are shown in the graph on the right. The graph depicting the fold change in Ku foci intensity in each condition corresponds to . (E) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 5 or 60 min with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the change in Ku foci intensity with NEDi versus without NEDi (DMSO) is plotted in the graph on the right. The graph in depicts the fold change in Ku foci intensity in each condition. (F) WT, PKcs-KO, or LIG4-KO U2OS cells incubated with 3 μM <t>NU7441</t> (PKi) were treated with 3 nM Cali for 1 h with or without NEDi before being collected and processed to separate the chromatin fraction from the soluble fraction, which were both analyzed by immunoblotting. SAF-A and nucleolin were used as loading controls for the chromatin and the soluble fraction, respectively. (G) Control (immunoglobulin G [IgG]) or anti-Ku immunoprecipitation was performed from the soluble fractions of PKcs-KO U2OS to monitor Ku ubiquitination in response to Cali with or without NEDi. For all panels, error bars represent SD from the means of n ≥ 3 independent experiments. p values are as follow: ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Scale bars, 5 μm.
    Dna Pk Inhibitor Nu7441, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dna pk inhibitor nu7441/product/Tocris
    Average 95 stars, based on 1 article reviews
    dna pk inhibitor nu7441 - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Immunoblot of U2OS cells that are wild type (WT) or knocked out for the indicated genes. See for the IR sensitivity analysis of each of these cells. (B) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO received 5 Gy of IR before being post-incubated 5 or 60 min and processed for Ku foci imaging. Representative pictures are shown on the left. Ku foci intensity was measured and normalized to the average Ku foci intensity measured after 5 Gy of IR in WT U2OS to compute the fold change in Ku foci intensity in each condition, depicted on the graph on the right. (C) WT or PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 60 min before being processed for Ku foci imaging. Cells were pre-treated with nedisertib (PKi) for 1 h before treatment where indicated. Fold change in Ku foci intensity in each condition is displayed. (D) PKcs-KO or LIG4-KO U2OS cells received 5 Gy of IR and were post-incubated for the indicated time with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the changes in Ku foci intensity with NEDi versus without NEDi (DMSO) are shown in the graph on the right. The graph depicting the fold change in Ku foci intensity in each condition corresponds to . (E) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 5 or 60 min with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the change in Ku foci intensity with NEDi versus without NEDi (DMSO) is plotted in the graph on the right. The graph in depicts the fold change in Ku foci intensity in each condition. (F) WT, PKcs-KO, or LIG4-KO U2OS cells incubated with 3 μM NU7441 (PKi) were treated with 3 nM Cali for 1 h with or without NEDi before being collected and processed to separate the chromatin fraction from the soluble fraction, which were both analyzed by immunoblotting. SAF-A and nucleolin were used as loading controls for the chromatin and the soluble fraction, respectively. (G) Control (immunoglobulin G [IgG]) or anti-Ku immunoprecipitation was performed from the soluble fractions of PKcs-KO U2OS to monitor Ku ubiquitination in response to Cali with or without NEDi. For all panels, error bars represent SD from the means of n ≥ 3 independent experiments. p values are as follow: ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Scale bars, 5 μm.

    Journal: Cell reports

    Article Title: Identification of the main barriers to Ku accumulation in chromatin

    doi: 10.1016/j.celrep.2024.114538

    Figure Lengend Snippet: (A) Immunoblot of U2OS cells that are wild type (WT) or knocked out for the indicated genes. See for the IR sensitivity analysis of each of these cells. (B) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO received 5 Gy of IR before being post-incubated 5 or 60 min and processed for Ku foci imaging. Representative pictures are shown on the left. Ku foci intensity was measured and normalized to the average Ku foci intensity measured after 5 Gy of IR in WT U2OS to compute the fold change in Ku foci intensity in each condition, depicted on the graph on the right. (C) WT or PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 60 min before being processed for Ku foci imaging. Cells were pre-treated with nedisertib (PKi) for 1 h before treatment where indicated. Fold change in Ku foci intensity in each condition is displayed. (D) PKcs-KO or LIG4-KO U2OS cells received 5 Gy of IR and were post-incubated for the indicated time with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the changes in Ku foci intensity with NEDi versus without NEDi (DMSO) are shown in the graph on the right. The graph depicting the fold change in Ku foci intensity in each condition corresponds to . (E) WT, PKcs-KO, LIG4-KO, or LIG4/PKcs-KO U2OS cells received 5 Gy of IR and were post-incubated for 5 or 60 min with or without NEDi before being processed for Ku foci imaging. Representative pictures are shown on the left, while the ratio between the change in Ku foci intensity with NEDi versus without NEDi (DMSO) is plotted in the graph on the right. The graph in depicts the fold change in Ku foci intensity in each condition. (F) WT, PKcs-KO, or LIG4-KO U2OS cells incubated with 3 μM NU7441 (PKi) were treated with 3 nM Cali for 1 h with or without NEDi before being collected and processed to separate the chromatin fraction from the soluble fraction, which were both analyzed by immunoblotting. SAF-A and nucleolin were used as loading controls for the chromatin and the soluble fraction, respectively. (G) Control (immunoglobulin G [IgG]) or anti-Ku immunoprecipitation was performed from the soluble fractions of PKcs-KO U2OS to monitor Ku ubiquitination in response to Cali with or without NEDi. For all panels, error bars represent SD from the means of n ≥ 3 independent experiments. p values are as follow: ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Scale bars, 5 μm.

    Article Snippet: NU7441 (studies in human) , Tocris , Cat# 3712.

    Techniques: Western Blot, Incubation, Imaging, Control, Immunoprecipitation

    Journal: Cell reports

    Article Title: Identification of the main barriers to Ku accumulation in chromatin

    doi: 10.1016/j.celrep.2024.114538

    Figure Lengend Snippet:

    Article Snippet: NU7441 (studies in human) , Tocris , Cat# 3712.

    Techniques: Generated, Recombinant, Plasmid Preparation, Modification, Software